LANCET The angiotensin receptor blocker candesartan prolongs survival in patients with chronic heart failure regardless of whether they are taking an ACE inhibitor, a large study shows.The addition of candesartan (Atacand) 32mg daily to an ACE inhibitor and beta blocker in patients with impaired left-ventricular function resulted in a 15% reduction in mortality and hospitalisation, researchers told the European Society of Cardiology congress in Vienna, Austria.Our findings are consistent with the evidence that angiotensin II continues to be produced despite chronic ACE inhibitor treatment,” the researchers said.Adding an angiotensin-receptor blocker to conventional treatment has clinical benefit.”In the CHARM trial, sponsored by AstraZeneca, maker of Atacand, patients not receiving an ACE inhibitor because of intolerance, had a 23% reduction in cardiac...
The content on this site is available to Australian Registered Health Practitioners only. Please login or register for access.